PRIMARY OBJECTIVES:~I. To estimate the response rate and time-to-progression (TTP) in previously treated patients with low grade non-Hodgkin's lymphoma treated with thalidomide.~II. To evaluate the effect of thalidomide on microvascular density in the bone marrow of patients with low grade cell non-Hodgkin's lymphoma.~III. To evaluate the effects of thalidomide on bFGF levels in serum and urine.~OUTLINE:~Patients receive oral thalidomide once daily. Treatment continues in the absence of disease progression or unacceptable toxicity.~Patients are followed every 6 months for 2 years and then annually for 3 years.~PROJECTED ACCRUAL: A total of 21-45 patients will be accrued for this study.
Phase II trial to study the effectiveness of thalidomide in treating patients who have relapsed or refractory low-grade non-Hodgkin's lymphoma. Thalidomide may stop the growth of non-Hodgkin's lymphoma by stopping blood flow to the tumor